What is HC Wainwright’s Estimate for CANF FY2026 Earnings?

Can-Fite BioPharma Ltd. (NYSE:CANF) – Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Can-Fite BioPharma in a research report issued to clients and investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.68) for the year, up from their prior estimate of ($1.04). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at ($0.27) EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.39 EPS.

CANF has been the subject of a number of other research reports. Zacks Research upgraded shares of Can-Fite BioPharma to a “hold” rating in a research report on Wednesday, May 13th. D. Boral Capital raised shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Can-Fite BioPharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Can-Fite BioPharma Stock Performance

CANF stock opened at $3.85 on Tuesday. The firm has a 50 day simple moving average of $3.24 and a 200 day simple moving average of $3.70. Can-Fite BioPharma has a 52 week low of $2.56 and a 52 week high of $21.00. The stock has a market cap of $2.52 million, a P/E ratio of -2.11 and a beta of 1.11.

Institutional Trading of Can-Fite BioPharma

A number of institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Can-Fite BioPharma during the 4th quarter worth $41,000. Rhumbline Advisers raised its holdings in shares of Can-Fite BioPharma by 42.4% during the 1st quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after purchasing an additional 11,388 shares in the last quarter. Finally, Sabby Management LLC lifted its stake in shares of Can-Fite BioPharma by 80.3% in the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after purchasing an additional 626,306 shares during the last quarter. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).